Ulcerative colitis is an autoimmune-inflammatory disease characterized by increased proliferation of colonic epithelial cells, dysregulation of signal transduction pathways, elevated mucosal T-cell activation, increased production of pro-inflammatory cytokines, and enhanced leukocyte infiltration into colonic interstitium. Several compounds that possess anti-proliferative properties and/or inhibit cytokine production exhibit a therapeutic effect in murine models of colitis. Mammalian target of rapamycin (mTOR), a protein kinase regulating cell proliferation, is implicated in colon carcinogenesis. In this study, we report that a novel haloacyl aminopyridine based molecule (P2281) is a mTOR inhibitor and is efficacious in a murine model of human colitis. In vitro studies using western blot analysis and cell-based ELISA assays showed that P2281 inhibits mTOR activity in colon cancer cells. In vitro and in vivo assays of pro-inflammatory cytokine production revealed that P2281 diminishes induced IFN-γ production but not TNF-α production indicating preferential inhibitory effects of P2281 on T-cell function.
Introduction
Ulcerative colitis (UC) 1 is an auto-immune/inflammatory disease affecting millions of people worldwide. Neither the initiating event nor the sequence of propagating events that lead to and sustain colitis have been fully elucidated. Nevertheless, it is increasingly clear that a dysfunctional immune-response, involving Toll-like receptor-4 (TLR-4) (17) and components of normal gastrointestinal enteric bacteria (24, 49) , plays a key role in the pathogenesis of colitis.
Thus, an early step is macrophage antigen presentation to activated mucosal T-cells (53) which leads to interferon (IFN) production and release (6) . Bacterial components (e.g., LPS) and IFNs trigger signal transduction cascades (e.g., NF-κB pathway; mTOR-STAT1 pathway) (4, 13) leading to increased proliferation of colonic epithelial cells (56) and elevated expression of proinflammatory genes (e.g. cytokines such as TNF-α) (8) . Pro-inflammatory cytokines stimulate leukocytes and endothelium leading to aberrant leukocyte recruitment and enhanced infiltration into damaged colonic interstitium (29, 38).
The above observations have led to therapeutic approaches that seek to diminish colitis (and related diseases) by attenuating the immune/inflammatory response. Indeed, in various experimental models of acute and/or chronic colitis (i) suppression of T-cell function (e.g., by cyclosporin A) (37) , (ii) blockade of signal transduction pathways (e.g., mTOR pathway, NF-κB pathway) (15, 34, 52) , (iii) inhibition of pro-inflammatory cytokine expression (3, 46) , and (iv) attenuation of leukocyte-endothelial interactions (1) separately provides a beneficial effect.
Mammalian target of rapamycin (mTOR) is a serine-threonine protein kinase that regulates protein synthesis, cell growth and cell proliferation in response to growth factors and nutrients (18, 40) . It is well-established that mTOR plays a crucial role in tumorogenesis (40) . More recently, accumulating evidence causally links increased mTOR activity to heightened inflammatory responses. Indeed, LPS stimulation of macrophages leads to the phosphorylation and activation of p70S6K1 as well as that of 4EBP1/PHAS-1 (13); both proteins are bonafide targets of mTOR. Moreover, the mTOR pathway regulates the production of nitric oxide (58) and activates STAT1-dependent transcription in macrophages in response to LPS (27).
Interestingly, a recent study showed that rapamycin, a mTOR inhibitor, blunts leukocyte adhesion and extravasation in the gut mucosa leading to suppression of experimental chronic colitis (15) . In a complementary study, treatment with everolimus (another mTOR inhibitor)
reduced the number of T-cells in lamina propria and blocked lymphocytic IFN-γ release thereby ameliorating established murine colitis (34) . These findings suggest that mTOR inhibitors may be useful for treatment of UC.
The pyridine scaffold is a very common structural motif that can be found in many natural products and in several pharmacologically interesting compounds (20, 22, 30) . Therefore, the synthesis of pyridine derivatives, with the objective of developing new drugs, is an active area of research. Indeed, (i) it has been claimed that 2-cyanopyridylureas derivatives can treat hyperproliferative and angiogenesis disorders (50) (ii) 3-cyano-2,6-dihydropyridine inhibits dihydrouracil dehydrogenase and its coadministration with 1-ethoxymethyl-5-fluorouracil enhances the antitumor effect (54), (iii) pyridothienopyrimidines exhibit cytotoxic activity (41).
In our general search for novel anti-cancer agents, we found that 2-chloro-N-(6-cyanopyridin-3-6 yl)propanamide (P2281; Fig. 1 antibody to phospho-p70S6K1-Thr39 (Cell Signaling; Danvers, MA) was added (diluted 1:500), and the cells were incubated at ambient temperature for 1 hr. After the incubation, the wells were washed and a peroxidase-conjugated polyclonal (secondary) antibody to rabbit IgG (Santa Cruz, CA) was added (diluted 1:500). Following 1 hr incubation at room temperature, the wells were washed and treated with o-phenylene diamine dihydrochloride (OPD; Sigma Aldrich; St.
Louis, MO). After a 5 min-incubation at room temperature, the reaction was stopped using H 2 SO 4 . The absorbance of the fluid in each well was determined at 490 nm using a microwell plate spectrophotometer (Molecular Devices, Sunnyvale, CA). In each experiment, rapamycin (0.2 µM; Sigma Aldrich) was used as a positive control for mTOR inhibition. In every experiment, each condition was run in triplicate wells.
Western blot analysis (45) was used to confirm the mTOR activity. H460 and/or HCT-116 cells were serum starved for 24 hr. Subsequently, the cells were pre-treated with P2281 or DMSO for Rockford, IL). The images were captured using a Kodak FX documentation system. In each in vitro experiment, rapamycin (1 µM) was used as a positive control for mTOR inhibition. To quantify the relative differences in phosphorylation, densitometry analysis was performed using the Quantity One software (Bio-Rad Laboratories) with high resolution "tiff" images. The optical density of each band was determined keeping the area and the pixel number constant.
Following background subtraction and normalization to the β-actin band, the % phosphorylation of the relevant protein (p4E-BP1 or p70S6K1) was calculated.
Pro-inflammatory cytokine production assay using hPBMCs: Regular blood was collected from normal healthy volunteers after informed consent. Peripheral blood mononuclear cells (hPBMC) were harvested using Ficoll-Hypaque density gradient centrifugation (1.077 g/ml;
Sigma Aldrich) (10 . Importantly, 30-40kDa DSS was utilized in this study for it is known to induce more severe colitis than 5kDa DSS and 500kDa DSS (25). For each mouse, weight, and rectal bleeding were determined every day following the introduction of DSS. DSS-induced colitis was assessed by macroscopic and histological analyses of the colon (described below). To probe the efficacy of P2281, a group of 6 mice were given daily i.p. injections of 15 mg/kg P2281 suspension in CMC. On the day of sacrifice, various parameters indicative of clinical disease were graded as mentioned in Table 1 .
All these parameters were lumped to obtain an overall clinical disease activity index.
Macroscopic Colon Assessment:
At the end of DSS treatment period, mice were anesthetized with urethane (1.5 g/kg, i.p.). Maximum possible quantity of blood was collected through abdominal aorta in a heparinized tube. Subsequently, the whole colon was excised. The colon was macrosopically assessed by determining (a) the presence or absence of blood and (b) the longitudinal length. The whole colon was utilized for histological analyses and/or western blot analysis.
Histological Analysis of Colon:
Colon biopsies from proximal colon, medial colon and distal colon were collected and fixed in neutral buffered formalin. Paraffin embedded sections (5µm thickness) of the colon specimens were stained with Mayer's hematoxyllin (Sigma Aldrich) and Eosin (Loba Chemie; Mumbai, India) and graded by an investigator blinded to the treatment groups. Histopathological scoring was performed based on presence of inflammatory cells, extent of crypt damage, erosions and over all architectural damage, each scored on a scale of 0 to 3 as described elsewhere (12) . Sections were scored for each feature separately and the scores added to arrive at the final histopathological scoring for individual colon specimen. Histological assessment of disease activity was carried out by analyzing the average histopathological score of a group.
Statistical Analysis: For analyzing differences between two groups, Student's T-test was used.
For analyzing differences among multiple (more than two) groups, a single factor ANOVA followed by Bonferroni's multiple pair-wise comparison tests was used. P values < 0.05 were considered statistically significant. Unless stated otherwise, all error bars represent standard error of mean.
Results

P2281, a haloacyl aminopyridine based molecule, inhibits mTOR activity in cancer cells
Prior studies have shown that pyridine based molecules are known to possess anti-proliferative properties (20, 22, 30) . mTOR is a protein kinase that regulates cell proliferation (18, 40) . Thus, in our attempt to identify novel anti-cancer agents we ascertained the effect of library compounds on mTOR activity. As part of this general screening process, we investigated the effect of P2281, a haloacyl aminopyridine based molecule ( TNF-α production from hPBMCs (Fig. 3A) . Rolipram, the positive control, significantly inhibited LPS-induced production of TNF-α (Fig. 3A) . However, P2281 had little, if any, effect on LPS-induced production of TNF-α (Fig. 3A) . Similar results were obtained with rapamycin (Fig. 3A) . These in vitro findings were corroborated by in vivo studies wherein P2281 did not inhibit LPS-induced TNF-α production (Fig. 3B ).
Given that everolimus, a mTOR inhibitor, inhibits IFN-γ production (34), we next investigated the effect of P2281 on the induced production of IFN-γ. Freshly isolated hPBMCs were pretreated with P2281 or 0.5% DMSO and subsequently stimulated with concanavalin A for 18 hrs.
ELISA of supernatants revealed that concanavalin stimulation induced IFN-γ production from hPBMCs ( Fig. 4A) . Cyclosporine A, the positive control, significantly inhibited concanavalininduced production of IFN-γ (Fig. 4A ). More importantly, P2281 also significantly inhibited concanavalin-induced production of IFN-γ (Fig. 4A) . Accordingly, dose-response studies were carried out. P2281 inhibited induced IFN-γ production in a dose dependent manner with significant inhibition being observed at P2281 concentration > 30 µM (Fig. 4B) . Rapamycin also inhibited concanavalin-induced IFN-γ production in a dose-dependent manner (data not shown). Collectively, these results clearly demonstrate that P2281 inhibits induced IFN-γ production but not induced TNF-α production.
P2281 suppresses DSS-induced colitis
The observations that rapamycin and evorilimus (both mTOR inhibitors) are efficacious in animal models of colitis (15, 34) , combined with the findings that blocking IFN-γ production elicits a therapeutic effect in experimental colitis (16) , led us hypothesize that P2281 (that inhibits mTOR activation as well as IFN-γ production) would be efficacious in a murine model of colitis. Accordingly, we investigated the effect of P2281 in an experimental model of colitis.
A group of 6 mice was given DSS solution from day 1 to 10. As a control for DSS treatment, a group of 6 mice was given regular drinking water from day 1 to 10 (normal mice; naïve).
Separate groups of mice (6 mice per group) were given DSS solution from day 1 to 10 and received daily injections of P2281 (15 mg/kg; i.p.) or 0.5% CMC (vehicle control for P2281).
The P2281 and CMC administration were started on the same day as DSS was added to the water. All mice were sacrificed after day 10 and macroscopic and histological analysis of the colon was performed.
As reported by others (48), DSS-induction of colitis was manifested with significant increase in clinical disease activity index associated with significant weight loss, presence of rectal bleeding, diarrhea and distinct occurrence of occult blood in feces (Fig. 5) . Consistent with these observations, DSS treatment significantly reduced the colon length (Fig. 5F ). CMC (vehicle control for P2281), given coincident with DSS treatment, had no effect on DSS-induced disease (data not shown). Importantly, P2281, given coincident with DSS treatment, significantly inhibited DSS-induced weight loss (Fig. 5A ) and significantly inhibited DSS-induced disease activity index (Fig. 5E ). In line with these observations, P2281 treatment significantly inhibited the DSS-induced shortening of the colon (Fig. 5F ). P2281 treatment diminished (albeit at not statistically significant levels) DSS-induced rectal bleeding (Fig. 5B ) and attenuated (albeit at not statistically significant levels) DSS-induced decreases in hemoglobin levels (Fig. 5D ).
Histological analysis confirmed the DSS-induction of colitis. As reported by others (25), colonic tissue sections from DSS mice, but not from normal mice, revealed severe inflammation, characterized by presence of edema, distinct inflammatory cellular infiltrate, extensive damage to mucosa and epithelium along with crypt destruction (Fig. 6A) . Remarkably, tissue sections from P2281-treated DSS mice, but not CMC-treated DSS mice, revealed attenuation in inflammation, characterized by suppression of edema, reduction in inflammatory cellular infiltrate, and protection against epithelium and crypt damage ( Fig. 6A and data not shown).
Accordingly, the histopathological score of P2281-treated DSS mice was significantly lower than that of CMC-treated DSS mice (Fig. 6B ).
Western blot analysis revealed that DSS induced phosphorylation of 4E-BP1 in the colon (Fig.   7 ). Consistent with in-vitro observations, P2281, at concentration efficacious in suppressing colitis, prominently suppressed DSS-induced phosphorylation of 4E-BP1 in colon (Fig. 7) . The relative differences in phosphorylation were quantified using densitometry. For this, the phosphorylation of the protein in the lysates from colon of CMC-treated DSS mice ( Fig. 7 ; Lane 2) was considered to be 100%. The phosphoprotein levels in the remaining samples were calculated with reference to the CMC-treated DSS mice. In P2281-treated DSS mice ( Fig. 7; Lane 3), the residual phosphorylation of 4E-BP1 was found to be 47% compared to 35% in naïve mice ( Fig. 7 ; Lane 1). Thus, P2281 treatment causes a marked reduction in DSS-induced mTOR activity.
Taken together, the above results clearly demonstrate that P2281 significantly inhibits DSSinduced macroscopic and histological abnormalities in the colon by inhibiting mTOR activation. In particular, P2281 dramatically suppresses edema, reduces leukocyte infiltration and maintains mucosal integrity in DSS-treated mice (Fig. 6A) . The results of our study are in line with observations from other studies (15, 34) and suggest that marked mTOR inhibitory activity ( Fig.   7 ) can elicit a meaningful physiological effect. Given that the macroscopic and microscopic manifestations of colitis observed in our system have been reported in other animal models of colitis and in humans (28), our data are likely broadly applicable to other experimental colitis models, and importantly to human colitis. Further experiments are warranted to confirm this hypothesis.
Discussion
The current therapies for inflammatory bowel disease include immunomodulating agents such as mesalazine, corticosteroids, and cyclosporine A (5). The latter is believed to act primarily through effects on T-cell function. P2281 inhibits mTOR activity and also suppresses induced production of IFN-γ (cytokine released by T-cells) (Figs. 2 and 4) . Interestingly, we found that P2281 failed to block in-vitro and in-vivo LPS-induced production of TNF-α (cytokine released by macrophages). The inability of P2281 to inhibit in-vivo LPS-induced TNF-α production was not because of pharmacokinetic issues for sufficient levels (C max : 38 µg/ml i.e., 180 µM) of P2281 were seen in the plasma of mice after administration of 100 mg/kg P2281 (data not shown). These observations, combined with the fact that LPS stimulates mTOR activity (13, 27) , indicate that mTOR activation plays little, if any, role in induced TNF-α production. (18) is in itself a fair indication of the importance of mTOR in oncology.
Moreover, due to their anti-proliferative effects on T and B cells, rapamycin (7) and its analogs have also been successfully used as immunosuppressants indicating that mTOR also plays a crucial role in functioning of the immune system. The activation of mTOR is governed by Akt (protein kinase B) which in turn is activated by the PI3K pathway (19, 32) . Thus, triggering of the PI3K-Akt-mTOR arm of the cellular signaling machinery in many cases is necessary and sufficient for tumorigenesis. Of note, the PI3K-Akt pathway has been implicated in colon carcinogenesis (44) . Interestingly, P2281 did not significantly inhibit the phosphorylation of Akt (18% inhibition; data not shown) indicating that it is a preferential mTOR inhibitor. Separately, overexpression of the protein synthesis initiation factor, eIF4E has been documented in colon cancers (42) . Given that mTOR positively regulates the function of eIF4E, it follows that mTOR is a critical target for colon cancer. A connection between Wnt and mTOR has also been reported. Wnt pathway can inactivate TSC1/2 proteins which are the negative regulators of mTOR, thus relieving the inhibition on mTOR (21) . The enhanced activation of mTOR would then drive colon carcinogenesis. mTOR activation was also shown to lead to chromosomal instability and the formation of colonic polyposis (2) . Taken together, these findings demonstrate the importance of targeting mTOR in colorectal cancer. Moreover, inflammatory disorders such as Crohn's disease and ulcerative colitis may also lead to colon cancer in the long run (14) . Our findings, thus, suggest that targeting mTOR may not only prevent colitis but also exert a further inhibitory effect on colon cancer development in inflammatory bowel disease patients.
In conclusion, we have demonstrated that P2281 is a novel mTOR inhibitor and that systemic application (i.p.) of P2281 significantly suppresses chemically-induced murine colitis. Thus, P2281 may be a potential therapeutic for ulcerative colitis with important implications for colon cancer too. 
